Bosch-Boonstra-Schaaf Optic Atrophy Syndrome

1. Disease Information

1.1 Concise overview (what is the disease?)

BBSOAS is a neurodevelopmental syndrome with prominent visual-system involvement. A 2022 review defines it as “a recently described monogenic neurodevelopmental syndrome caused by the haploinsufficiency of NR2F1 gene” (Cells 2022; doi:10.3390/cells11081260). (bertacchi2022pathophysiologicalheterogeneityof pages 2-5)

A large ophthalmology/neurodevelopment-focused cohort paper describes it as “an autosomal dominant disorder characterized by delayed neurodevelopment, moderate to severe intellectual disability and visual impairment.” (Brain Communications 2021; doi:10.1093/braincomms/fcab162). (jurkute2021pathogenicnr2f1variants pages 3-4)

1.2 Key identifiers and alternative names

Table: This table compiles the standardized identifiers and nomenclature for Bosch–Boonstra–Schaaf optic atrophy syndrome that were explicitly supported by the retrieved evidence. It also marks major resources where identifiers were not retrieved in this run, which helps distinguish confirmed facts from gaps in the current evidence collection.

Common synonyms / alternative names (as used in retrieved literature): - Bosch–Boonstra–Schaaf optic atrophy syndrome (BBSOAS) (bertacchi2022pathophysiologicalheterogeneityof pages 2-5, jurkute2021pathogenicnr2f1variants pages 3-4) - Bosch–Boonstra–Schaaf optic atrophy (BBSOA) syndrome (variant abbreviation used in some papers) (bertacchi2019mousenr2f1haploinsufficiency pages 1-2) - NR2F1-related neurodevelopmental disorder (broader terminology used in recent discussions) (tang2025casereporta pages 7-7)

1.3 Evidence source types

The information synthesized here is derived from: - Aggregated disease-level resources and synthesis reviews (Cells 2022) (bertacchi2022pathophysiologicalheterogeneityof pages 2-5) - Human case series/cohort deep-phenotyping (n=22) (Brain Communications 2021) (jurkute2021pathogenicnr2f1variants pages 1-3) - Human case reports and genotype-group literature syntheses (Frontiers in Medicine 2025; case-based meta-summary table) (tang2025casereporta pages 6-7) - Model organism studies (mouse) providing mechanistic support (EMBO Mol Med 2019; HMG 2020; DMM 2023) (bertacchi2019mousenr2f1haploinsufficiency pages 1-2, chen2020nr2f1heterozygousknockout pages 3-3, bonzano2023nr2f1shapesmitochondria pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic cause (primary): Pathogenic variants or deletions affecting NR2F1 cause BBSOAS; the dominant mechanism is NR2F1 haploinsufficiency, with evidence that some variants may also produce dominant-negative effects. (bertacchi2022pathophysiologicalheterogeneityof pages 2-5, bonzano2023nr2f1shapesmitochondria pages 1-2)

Mechanistic framing: NR2F1 is a nuclear receptor transcription factor with conserved DNA-binding and ligand-binding domains; disease-associated variants cluster in these functional domains and disrupt transcriptional regulation during brain and eye development. (bertacchi2022pathophysiologicalheterogeneityof pages 2-5, jurkute2021pathogenicnr2f1variants pages 3-4)

2.2 Risk factors

Because BBSOAS is Mendelian and largely de novo, “risk factors” are primarily genetic: - De novo variants are common: the 2022 review summarizes that most variants were diagnosed as de novo (73.9%), with some familial cases (7.6%) and a subset due to deletions (16.3%). (bertacchi2022pathophysiologicalheterogeneityof pages 2-5) - Variant location correlates with phenotype severity: DBD variants show higher rates of epilepsy and ASD in a genotype-group comparison (see Section 4). (tang2025casereporta pages 6-7)

No environmental risk factors were identified in the retrieved evidence set.

2.3 Protective factors / gene–environment interactions

No protective factors or gene–environment interactions were identified in the retrieved evidence set; the disorder is primarily driven by NR2F1 dosage/function. (bertacchi2022pathophysiologicalheterogeneityof pages 2-5)

3. Phenotypes

3.1 Core phenotype spectrum and frequencies

BBSOAS is characterized by multi-system neurodevelopmental and ocular phenotypes.

Table: This table summarizes phenotype frequencies, onset patterns, and progression notes for Bosch–Boonstra–Schaaf optic atrophy syndrome using the retrieved review, case-series, and genotype–phenotype comparison evidence. It is useful for rapid knowledge-base extraction of common manifestations and associated HPO terms.

Key quantitative phenotype data from the 2022 synthesis review include: DD (~88%), ID (~85.9%), optic atrophy (~66.3%), cortical visual impairment (~44.6%), epilepsy (~46.7%), hypotonia (~62%), hearing impairment (~11%), ASD/autistic traits (~39.1% ASD; 14.1% autistic traits). (bertacchi2022pathophysiologicalheterogeneityof pages 15-17)

3.2 Ophthalmologic phenotyping and natural history

A deep phenotyping study of 22 individuals carrying pathogenic NR2F1 variants reported early-childhood onset of visual impairment, with “small and/or tilted hypoplastic optic nerves observed in 10 cases,” and OCT/electrophysiology evidence supporting retinal ganglion cell (RGC) involvement. Longitudinal data suggested stability: “there was no significant deterioration in visual function during the period of follow-up.” (jurkute2021pathogenicnr2f1variants pages 1-3)

3.3 Quality-of-life and functional impact

Although disease-specific QoL instruments were not retrieved in this run, the phenotypes imply significant functional impact: - Visual impairment (optic nerve hypoplasia/atrophy; CVI) affects learning, mobility, and communication (jurkute2021pathogenicnr2f1variants pages 1-3, bertacchi2022pathophysiologicalheterogeneityof pages 18-20) - DD/ID, speech delay, hypotonia, seizures, and ASD traits affect educational needs and adaptive functioning (bertacchi2022pathophysiologicalheterogeneityof pages 15-17)

4. Genetic / Molecular Information

4.1 Causal gene

NR2F1 (COUP-TFI) is the established causal gene; BBSOAS is linked to NR2F1 haploinsufficiency. (bertacchi2022pathophysiologicalheterogeneityof pages 2-5, jurkute2021pathogenicnr2f1variants pages 3-4)

4.2 Pathogenic variant spectrum and genotype–phenotype notes

Table: This table summarizes the NR2F1 variant classes reported for Bosch–Boonstra–Schaaf optic atrophy syndrome / NR2F1-related neurodevelopmental disorder and the main genotype–phenotype patterns supported by the retrieved literature. It is useful for linking variant location to disease severity, especially ocular and neurodevelopmental features.

Genotype–phenotype correlations (examples supported by retrieved evidence): - Optic atrophy frequency differs by variant class: DBD variants (78%), translation-initiation variants (78%), frameshift/truncations (72%), LBD variants (47%). (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) - In a genotype-group comparison (DBD vs non-DBD), epilepsy and ASD were significantly more frequent in the DBD group (epilepsy 66.67% vs 34.38%, p=0.002; ASD 61.11% vs 35.94%, p=0.015). (tang2025casereporta pages 6-7)

4.3 Variant interpretation frameworks

Clinical variant classification and reclassification using ACMG/AMP principles is highlighted in recent case literature. (tang2025casereporta pages 6-7, tang2025casereporta pages 7-7)

5. Environmental Information

No non-genetic environmental contributors, lifestyle factors, or infectious triggers were identified in the retrieved sources; the disorder is primarily genetic. (bertacchi2022pathophysiologicalheterogeneityof pages 2-5)

6. Mechanism / Pathophysiology

6.1 Mechanistic causal chain (integrated view)

A coherent mechanistic chain supported by the retrieved literature is: 1) NR2F1 loss-of-function perturbs transcriptional regulation during neurodevelopment (bertacchi2022pathophysiologicalheterogeneityof pages 2-5, jurkute2021pathogenicnr2f1variants pages 3-4) 2) In the visual system, this contributes to abnormal retinogenesis, reduced RGC density, and disrupted RGC axon guidance into the optic stalk (mouse data) and to RGC dysfunction/ganglion cell layer thinning (human OCT/electrophysiology), producing congenital/early-childhood visual impairment that appears often non-progressive in available follow-up (jurkute2021pathogenicnr2f1variants pages 1-3) 3) In optic nerve, mouse haploinsufficiency causes oligodendrocyte–astrocyte imbalance, postnatal hypomyelination and astrogliosis, slowing conduction from retina to higher visual centers and impairing visual learning (bertacchi2019mousenr2f1haploinsufficiency pages 1-2) 4) In broader neurodevelopmental circuitry, Nr2f1 haploinsufficiency impairs hippocampal synaptic plasticity (reduced LTP/LTD), providing a plausible mechanism for ID and learning/memory phenotypes; transcriptomics reveal differential expression including upregulated MMPs (chen2020nr2f1heterozygousknockout pages 3-3) 5) Newer mechanistic work suggests NR2F1 also regulates nuclear-encoded mitochondrial genes, with reduced mitochondrial mass/fragmentation and reduced newborn neuron survival/integration, implicating mitochondrial dysfunction in pathogenesis (bonzano2023nr2f1shapesmitochondria pages 1-2)

6.2 Ontology suggestions (GO/CL/UBERON)

Table: This table maps major disease mechanisms in Bosch-Boonstra-Schaaf optic atrophy syndrome to suggested GO, CL, and UBERON ontology terms. It is designed to support structured knowledge-base annotation of pathophysiology, affected cell types, and anatomical sites.

7. Anatomical Structures Affected

Primary systems/organs: - Eye/visual system: retina (RGC layer), optic nerve/optic nerve head, extracortical visual pathways (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants media 1490a58e) - Central nervous system: hippocampus/dentate gyrus (synaptic plasticity; adult neurogenic niche), broader cortical/white matter structures (chen2020nr2f1heterozygousknockout pages 3-3, bonzano2023nr2f1shapesmitochondria pages 1-2)

Lateralization: Visual phenotypes are generally described bilaterally in clinical contexts; explicit laterality statistics were not retrieved. (jurkute2021pathogenicnr2f1variants pages 1-3)

8. Temporal Development

Typical onset: pediatric/infancy. During infancy, symptoms may be non-specific (hypotonia, feeding difficulties, epilepsy, poor eye tracking), with more specific BBSOAS features becoming evident over the first years of life. (bertacchi2022pathophysiologicalheterogeneityof pages 18-20)

Progression: Visual impairment may be largely non-progressive in longitudinal ophthalmic follow-up in at least some patients, and a review cites a “stable, non-progressive reduction in visual acuity.” (jurkute2021pathogenicnr2f1variants pages 1-3, bertacchi2022pathophysiologicalheterogeneityof pages 15-17)

9. Inheritance and Population

Inheritance pattern: autosomal dominant (jurkute2021pathogenicnr2f1variants pages 3-4)

De novo vs familial: the review summarizes most variants as de novo (73.9%) with some familial cases (7.6%) and deletions (16.3% of clinically described patients). (bertacchi2022pathophysiologicalheterogeneityof pages 2-5)

Epidemiology: Precise prevalence/incidence for BBSOAS was not retrieved in the accessible evidence. The review notes that inherited optic neuropathies overall have an estimated prevalence of 1 in 10,000 (not specific to BBSOAS). (bertacchi2022pathophysiologicalheterogeneityof pages 18-20)

10. Diagnostics

10.1 Clinical and functional testing

Key diagnostic and characterization modalities used in practice and in cohorts include neuro-ophthalmologic examination, OCT, ERG/VEP, and MRI/DTI tractography when available. (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants pages 3-4)

10.2 Genetic testing approach

A 2022 review recommends diagnostic evaluation for BBSOAS in individuals with optic nerve hypoplasia or optic atrophy plus DD/ID, noting that most diagnoses occur via genome-wide technologies: CMA for deletions and WES/large NGS panels for SNVs/indels. (bertacchi2022pathophysiologicalheterogeneityof pages 18-20)

Implementation table: | Domain | Recommended evaluation or therapy | Implementation notes | Suggested MAXO terms and LOINC/imaging modalities | Evidence source | |---|---|---|---|---| | Vision | Comprehensive neuro-ophthalmologic examination | Initial workup should document visual impairment, optic nerve anomalies, strabismus/nystagmus, and functional vision; visual impairment in BBSOAS often becomes apparent in early childhood and may be non-progressive on follow-up | MAXO: visual function rehabilitation; Imaging/modalities: fundus photography, optical coherence tomography (OCT), visual evoked potentials (VEP), electroretinography (ERG) (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants pages 3-4) | Deep phenotyping study of 22 individuals; review and management summary (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants pages 3-4, bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Vision | Visual therapy focused on cortical visual impairment (CVI) | Recommended supportive intervention when CVI is present; real-world implementation is rehabilitative rather than disease-modifying | MAXO: visual rehabilitation / visual therapy; modality: CVI-focused assessment and therapy (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | Review with recommended therapeutic approaches table (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Vision | OCT assessment of retinal ganglion cell layer and RNFL | High-resolution OCT can confirm retinal ganglion cell loss/ganglion cell layer thinning and support distinction between developmental optic nerve hypoplasia and degenerative optic atrophy | Imaging/modality: optical coherence tomography (OCT) of macula/optic nerve head (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants pages 3-4) | Human cohort with structural ocular phenotyping (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants pages 3-4) | | Vision | Electrophysiology of visual pathway | Pattern/flash VEP and ERG are useful to document retinal ganglion cell dysfunction and visual pathway conduction abnormalities | LOINC/imaging modalities: pattern VEP, flash VEP, full-field ERG, pattern ERG (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants pages 3-4) | Human cohort methods and findings (jurkute2021pathogenicnr2f1variants pages 1-3, jurkute2021pathogenicnr2f1variants pages 3-4) | | Neurology | Brain MRI with attention to corpus callosum, optic pathways, cortical malformations, delayed myelination | Neuroimaging abnormalities are common in reported patients; MRI helps assess syndromic involvement and differential diagnosis | Imaging/modality: brain MRI; diffusion tensor imaging/tractography where available (bertacchi2022pathophysiologicalheterogeneityof pages 15-17, bertacchi2022pathophysiologicalheterogeneityof pages 18-20, jurkute2021pathogenicnr2f1variants pages 1-3) | Case aggregation/review and ophthalmic-neuroimaging cohort data (bertacchi2022pathophysiologicalheterogeneityof pages 15-17, bertacchi2022pathophysiologicalheterogeneityof pages 18-20, jurkute2021pathogenicnr2f1variants pages 1-3) | | Neurology | EEG when seizures/epilepsy or infantile spasms are suspected | Epilepsy is frequent in BBSOAS; EEG is part of workup for seizure phenotypes and can guide anti-seizure treatment | LOINC/modality: electroencephalography (EEG); MAXO: antiseizure medication therapy / anticonvulsive treatment (bertacchi2022pathophysiologicalheterogeneityof pages 15-17, bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | Review of phenotype spectrum and recommended therapies (bertacchi2022pathophysiologicalheterogeneityof pages 15-17, bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Neurology | Anti-convulsive treatment if epilepsy is present | Symptomatic management only; no disease-specific therapy established | MAXO: anticonvulsant treatment / seizure management (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, tang2025casereporta pages 6-7) | Review therapeutic table; later case report notes no specific treatment exists beyond symptomatic care (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, tang2025casereporta pages 6-7) | | Development | Developmental assessment for developmental delay/intellectual disability | Evaluate speech, motor, cognition, behavior, adaptive function; DD and ID are among the most common features | MAXO: developmental assessment; neuropsychological evaluation (bertacchi2022pathophysiologicalheterogeneityof pages 15-17, bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | Review synthesizing common features and care recommendations (bertacchi2022pathophysiologicalheterogeneityof pages 15-17, bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Development | Physical therapy | Aims to increase strength and improve gross motor skills, especially relevant for hypotonia/poor coordination | MAXO: physical therapy (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | Review therapeutic table (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Development | Occupational therapy | Aims to improve fine motor skills and coordination | MAXO: occupational therapy (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | Review therapeutic table (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Development | Speech therapy, with sign language and alternative/augmentative communication when needed | Useful for speech delay and communication impairment; review specifically recommends considering sign language and alternative communication devices | MAXO: speech therapy; augmentative and alternative communication support (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, bertacchi2022pathophysiologicalheterogeneityof pages 15-17) | Review therapeutic table and phenotype summary (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, bertacchi2022pathophysiologicalheterogeneityof pages 15-17) | | Development/Behavior | Applied behavioral analysis (ABA) therapy if ASD is diagnosed | Consider when autism spectrum disorder or autistic traits are clinically confirmed | MAXO: behavioral therapy / applied behavior analysis (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | Review therapeutic table (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Hearing | Full hearing evaluation | Recommended every two years in the review; hearing impairment is less common but documented | Modality: audiology/hearing assessment, brainstem auditory pathway testing where indicated (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, bertacchi2022pathophysiologicalheterogeneityof pages 15-17) | Review follow-up recommendations and phenotype summary (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, bertacchi2022pathophysiologicalheterogeneityof pages 15-17) | | Genetics | Diagnostic evaluation for BBSOAS in any person with ONH or OA plus developmental delay/ID | During infancy, suspicion may arise from hypotonia, feeding difficulties, epilepsy, and poor eye tracking, even before full phenotype is evident | MAXO: genetic counseling; genomic diagnostic evaluation (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | Review diagnostic recommendation (bertacchi2022pathophysiologicalheterogeneityof pages 18-20) | | Genetics | Chromosomal microarray analysis (CMA) for deletions | Appropriate first-line genome-wide technology when copy-number loss of NR2F1 or nearby region is suspected | Modality: chromosome microarray analysis (CMA) (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, bertacchi2022pathophysiologicalheterogeneityof pages 5-7) | Review discussing deletions and diagnostic technologies (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, bertacchi2022pathophysiologicalheterogeneityof pages 5-7) | | Genetics | Whole-exome sequencing (WES) or large next-generation sequencing panels for SNVs/indels | Most individuals are expected to be diagnosed using genome-wide sequencing technologies because no pathognomonic clinical feature exists | Modality: WES; multigene NGS panel; single-gene NR2F1 analysis where phenotype strongly suggests diagnosis (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, kocaaga2022novelnr2f1variant pages 1-1) | Review diagnostic recommendation and case report identified by WES (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, kocaaga2022novelnr2f1variant pages 1-1) | | Genetics | Variant interpretation under ACMG/AMP framework | Important because missense variants, especially in the DNA-binding domain, may require structured interpretation and can correlate with severity | MAXO: clinical molecular diagnosis; framework: ACMG/AMP variant classification (tang2025casereporta pages 6-7, tang2025casereporta pages 7-7) | 2025 case report and literature summary citing ACMG/AMP use and genotype-phenotype observations (tang2025casereporta pages 6-7, tang2025casereporta pages 7-7) | | Multidisciplinary follow-up | Coordinated ophthalmology, neurology, developmental pediatrics/rehabilitation, audiology, and genetics follow-up | Real-world care is supportive and longitudinal; no approved disease-modifying therapy currently exists | MAXO: multidisciplinary care management (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, tang2025casereporta pages 6-7) | Review recommendations and recent case report noting symptomatic management only (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, tang2025casereporta pages 6-7) |

Table: This table summarizes currently supported diagnostic evaluations and supportive management strategies for Bosch–Boonstra–Schaaf optic atrophy syndrome across vision, neurology, development, hearing, and genetics. It is useful for translating the literature into a practical, ontology-ready care framework for a disease knowledge base.

10.3 Visual evidence from figures (human + mouse)

OCT-based ganglion cell layer thinning, tractography abnormalities in visual pathways, and mouse retinal developmental phenotypes are shown in figures extracted from Jurkute et al. 2021. (jurkute2021pathogenicnr2f1variants media 1490a58e, jurkute2021pathogenicnr2f1variants media 412f5e0a, jurkute2021pathogenicnr2f1variants media 964f2122, jurkute2021pathogenicnr2f1variants media 3c2b8d85)

11. Outcome / Prognosis

Vision: Available longitudinal ophthalmologic data in the 22-person cohort suggested no significant deterioration in visual function during follow-up, supporting a congenital/developmental and often non-progressive component. (jurkute2021pathogenicnr2f1variants pages 1-3)

Neurodevelopment: DD/ID and neurobehavioral features are chronic and variable, with substantial heterogeneity and possible genotype associations. Long-term prognosis statistics (life expectancy, mortality) were not retrieved in this run. (bertacchi2022pathophysiologicalheterogeneityof pages 15-17)

12. Treatment

12.1 Standard of care (supportive and rehabilitative)

A 2022 review compiles recommended therapeutic approaches, emphasizing supportive care: visual therapy for CVI; PT/OT; speech therapy with AAC/sign language considerations; ABA therapy for ASD; anticonvulsant treatment for epilepsy; and periodic hearing evaluation. (bertacchi2022pathophysiologicalheterogeneityof pages 18-20)

12.2 Recent developments (2024): perampanel for NR2F1-related epilepsy

A 2024 Acta Epileptologica study reports six new BBSOAS cases with epilepsy and a pooled analysis (n=20 total) suggesting: - Infantile epileptic spasms comprise a majority of NR2F1-related epilepsy cases (e.g., 60% or 65% depending on cohort inclusion detail) (li2024effectivetreatmentof pages 1-2, li2024effectivetreatmentof pages 14-15) - Previously reported cases had seizure control in only 50% (li2024effectivetreatmentof pages 1-2) - In the six new cases, “all … became seizure-free after perampanel as an add-on treatment,” with average time from add-on to seizure control 7.33 ± 4.59 months and mean required dose 0.22 ± 0.17 mg/kg/day; median time to seizure freedom 14 months (range 1–32 months). (li2024effectivetreatmentof pages 1-2)

This is promising but remains observational and may not generalize beyond the small sample. (li2024effectivetreatmentof pages 15-17)

12.3 Experimental / preclinical therapeutic signals

In an Nr2f1 haploinsufficient mouse model, “optic nerve hypomyelination … could be rescued by chemical drug treatment in early postnatal life,” indicating that at least some downstream pathology may be modifiable in principle, although this is not yet a validated human therapy. (bertacchi2019mousenr2f1haploinsufficiency pages 1-2)

Key direct quotes supporting treatment/mechanisms:

“Here, we review the pathophysiology of the Bosch–Boonstra–Schaaf Optic Atrophy Syndrome (BBSOAS; OMIM 615722; ORPHA 401777), a recently described monogenic neurodevelopmental syndrome caused by the haploinsufficiency of NR2F1 gene, a key transcriptional regulator of brain development.” Cells, 2022, doi:10.3390/cells11081260, https://doi.org/10.3390/cells11081260 (bertacchi2022pathophysiologicalheterogeneityof pages 2-5)

“BBSOAS is an autosomal dominant disorder characterized by delayed neurodevelopment, moderate to severe intellectual disability and visual impairment.” Brain Communications, 2021, doi:10.1093/braincomms/fcab162, https://doi.org/10.1093/braincomms/fcab162 (jurkute2021pathogenicnr2f1variants pages 3-4)

“The visual impairment became apparent in early childhood with small and/or tilted hypoplastic optic nerves observed in 10 cases.” Brain Communications, 2021, doi:10.1093/braincomms/fcab162, https://doi.org/10.1093/braincomms/fcab162 (jurkute2021pathogenicnr2f1variants pages 1-3)

“Interestingly, for those individuals with available longitudinal ophthalmological data, there was no significant deterioration in visual function during the period of follow-up.” Brain Communications, 2021, doi:10.1093/braincomms/fcab162, https://doi.org/10.1093/braincomms/fcab162 (jurkute2021pathogenicnr2f1variants pages 1-3)

“The clinical observations in our study cohort, supported by the mouse data, suggest an early neurodevelopmental origin for the retinal and optic nerve head defects caused by NR2F1 pathogenic variants, resulting in congenital vision loss that seems to be non-progressive.” Brain Communications, 2021, doi:10.1093/braincomms/fcab162, https://doi.org/10.1093/braincomms/fcab162 (jurkute2021pathogenicnr2f1variants pages 1-3)

“Notably, Nr2f1-deficient optic nerves develop an imbalance between oligodendrocytes and astrocytes leading to postnatal hypomyelination and astrogliosis.” EMBO Molecular Medicine, 2019, doi:10.15252/emmm.201910291, https://doi.org/10.15252/emmm.201910291 (bertacchi2019mousenr2f1haploinsufficiency pages 1-2)

“Importantly, some of these clinical features, such the optic nerve hypomyelination, could be rescued by chemical drug treatment in early postnatal life.” EMBO Molecular Medicine, 2019, doi:10.15252/emmm.201910291, https://doi.org/10.15252/emmm.201910291 (bertacchi2019mousenr2f1haploinsufficiency pages 1-2)

“Our data point to an active role for NR2F1 in the mitochondrial gene expression regulatory network in neurons and support the involvement of mitochondrial dysfunction in BBSOAS pathogenesis.” Disease Models & Mechanisms, 2023, doi:10.1242/dmm.049854, https://doi.org/10.1242/dmm.049854 (bonzano2023nr2f1shapesmitochondria pages 1-2)

“The discovery of impaired hippocampal synaptic plasticity in the heterozygous mouse model sheds light on the pathophysiology of altered memory and cognitive function in BBSOAS.” Human Molecular Genetics, 2020, doi:10.1093/hmg/ddz233, https://doi.org/10.1093/hmg/ddz233 (chen2020nr2f1heterozygousknockout pages 3-3)

“Perampanel exhibits dramatic efficacy for NR2F1 -related epilepsy.” Acta Epileptologica, 2024, doi:10.1186/s42494-023-00145-0, https://doi.org/10.1186/s42494-023-00145-0 (li2024effectivetreatmentof pages 1-2)

Blockquote: This artifact compiles exact high-value quotes from core BBSOAS papers supporting disease definition, phenotype, non-progressive visual impairment, mechanistic findings, and a recent treatment signal for NR2F1-related epilepsy.

13. Prevention

No primary prevention is available for a dominantly inherited/de novo neurodevelopmental disorder. Practical prevention is limited to: - Genetic counseling for families with an affected individual - Consideration of cascade testing in familial cases

These prevention-oriented recommendations are consistent with the genetic diagnostic framing emphasized in the review (genome-wide testing; lack of pathognomonic features). (bertacchi2022pathophysiologicalheterogeneityof pages 18-20)

14. Other Species / Natural Disease

No naturally occurring veterinary analogs were retrieved in this run. The key comparative evidence is from engineered mouse models (Section 15). (bertacchi2019mousenr2f1haploinsufficiency pages 1-2)

15. Model Organisms

15.1 Mouse models and phenotype recapitulation

Multiple mouse-model studies recapitulate major BBSOAS-relevant phenotypes: - Optic nerve / visual system model: Nr2f1 haploinsufficiency produces optic nerve atrophy-related features, including glial imbalance, hypomyelination, astrogliosis, and reduced conduction velocity; some features were chemically rescued early postnatally (EMBO Mol Med 2019; doi:10.15252/emmm.201910291). (bertacchi2019mousenr2f1haploinsufficiency pages 1-2) - Ocular developmental model aligned to human deep phenotyping: Nr2f1 mutant mice show decreased RGC density and disrupted RGC axon guidance, consistent with congenital optic nerve hypoplasia and reduced visual acuity (Brain Communications 2021). (jurkute2021pathogenicnr2f1variants pages 1-3) - Neurodevelopment/behavior model: Nr2f1 heterozygous knockout mice show impaired hippocampal synaptic plasticity and altered learning/memory; RNA-seq shows differential expression including MMP upregulation (HMG 2020; doi:10.1093/hmg/ddz233). (chen2020nr2f1heterozygousknockout pages 3-3) - Mitochondrial mechanism model (2023): Conditional NR2F1 loss in adult hippocampal neurogenic niche reduces mitochondrial mass and increases fragmentation in newborn neurons and supports mitochondrial dysfunction as a contributor to BBSOAS pathogenesis (DMM 2023; doi:10.1242/dmm.049854). (bonzano2023nr2f1shapesmitochondria pages 1-2)

Notes on evidence gaps and limitations

• MONDO, MeSH, ICD-10/11 codes were not present in retrieved evidence; these identifiers should be added from dedicated ontology resources in a separate targeted retrieval step. (bertacchi2022pathophysiologicalheterogeneityof pages 18-20, jurkute2021pathogenicnr2f1variants pages 1-3)
• Epidemiology (prevalence/incidence) of BBSOAS specifically was not available in the retrieved evidence; only inherited optic neuropathy prevalence (1/10,000) was found, which should not be substituted for BBSOAS prevalence. (bertacchi2022pathophysiologicalheterogeneityof pages 18-20)
• Several relevant 2023–2024 papers were listed as unobtainable in this run (e.g., AJNR 2023 neuroimaging paper) and therefore cannot be cited for specific claims.

Visual evidence (figures)

The extracted figures from Jurkute et al. 2021 include a graphical abstract and key figures showing OCT ganglion cell layer thinning, tractography abnormalities, and mouse retinal developmental defects; these support the claim of a neurodevelopmental origin of visual impairment and RGC involvement. (jurkute2021pathogenicnr2f1variants media 1490a58e, jurkute2021pathogenicnr2f1variants media 412f5e0a, jurkute2021pathogenicnr2f1variants media 964f2122, jurkute2021pathogenicnr2f1variants media 3c2b8d85)

References

1. (bertacchi2022pathophysiologicalheterogeneityof pages 2-5): Michele Bertacchi, Chiara Tocco, Christian P. Schaaf, and Michèle Studer. Pathophysiological heterogeneity of the bbsoa neurodevelopmental syndrome. Cells, 11:1260, Apr 2022. URL: https://doi.org/10.3390/cells11081260, doi:10.3390/cells11081260. This article has 33 citations.

2. (jurkute2021pathogenicnr2f1variants pages 1-3): Neringa Jurkute, Michele Bertacchi, Gavin Arno, Chiara Tocco, Ungsoo Samuel Kim, Adam M Kruszewski, Robert A Avery, Emma C Bedoukian, Jinu Han, Sung Jun Ahn, Nikolas Pontikos, James Acheson, Indran Davagnanam, Richard Bowman, Marios Kaliakatsos, Alice Gardham, Emma Wakeling, Ngozi Oluonye, Maddy Ashwin Reddy, Elaine Clark, Elisabeth Rosser, Patrizia Amati-Bonneau, Majida Charif, Guy Lenaers, Isabelle Meunier, Sabine Defoort, Catherine Vincent-Delorme, Anthony G Robson, Graham E Holder, Luc Jeanjean, Antonio Martinez-Monseny, Mariona Vidal-Santacana, Chloé Dominici, Cedric Gaggioli, Nadia Giordano, Matteo Caleo, Grant T Liu, Genomics England Research Consortium, Andrew R Webster, Michèle Studer, and Patrick Yu-Wai-Man. Pathogenic nr2f1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Communications, Jul 2021. URL: https://doi.org/10.1093/braincomms/fcab162, doi:10.1093/braincomms/fcab162. This article has 29 citations and is from a peer-reviewed journal.

3. (bonzano2023nr2f1shapesmitochondria pages 1-2): Sara Bonzano, Eleonora Dallorto, Ivan Molineris, Filippo Michelon, Isabella Crisci, Giovanna Gambarotta, Francesco Neri, Salvatore Oliviero, Ruth Beckervordersandforth, Dieter Chichung Lie, Paolo Peretto, Serena Bovetti, Michèle Studer, and Silvia De Marchis. Nr2f1 shapes mitochondria in the mouse brain, providing new insights into bosch-boonstra-schaaf optic atrophy syndrome. Disease Models & Mechanisms, Jun 2023. URL: https://doi.org/10.1242/dmm.049854, doi:10.1242/dmm.049854. This article has 15 citations and is from a domain leading peer-reviewed journal.

4. (li2024effectivetreatmentof pages 1-2): Xiao Li, Kai Gao, Yutang Li, Yuehua Zhang, Han Zhang, and Yuwu Jiang. Effective treatment of nr2f1-related epilepsy with perampanel. Acta Epileptologica, Jan 2024. URL: https://doi.org/10.1186/s42494-023-00145-0, doi:10.1186/s42494-023-00145-0. This article has 2 citations.

5. (jurkute2021pathogenicnr2f1variants pages 3-4): Neringa Jurkute, Michele Bertacchi, Gavin Arno, Chiara Tocco, Ungsoo Samuel Kim, Adam M Kruszewski, Robert A Avery, Emma C Bedoukian, Jinu Han, Sung Jun Ahn, Nikolas Pontikos, James Acheson, Indran Davagnanam, Richard Bowman, Marios Kaliakatsos, Alice Gardham, Emma Wakeling, Ngozi Oluonye, Maddy Ashwin Reddy, Elaine Clark, Elisabeth Rosser, Patrizia Amati-Bonneau, Majida Charif, Guy Lenaers, Isabelle Meunier, Sabine Defoort, Catherine Vincent-Delorme, Anthony G Robson, Graham E Holder, Luc Jeanjean, Antonio Martinez-Monseny, Mariona Vidal-Santacana, Chloé Dominici, Cedric Gaggioli, Nadia Giordano, Matteo Caleo, Grant T Liu, Genomics England Research Consortium, Andrew R Webster, Michèle Studer, and Patrick Yu-Wai-Man. Pathogenic nr2f1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Communications, Jul 2021. URL: https://doi.org/10.1093/braincomms/fcab162, doi:10.1093/braincomms/fcab162. This article has 29 citations and is from a peer-reviewed journal.

6. (bertacchi2019mousenr2f1haploinsufficiency pages 1-2): Michele Bertacchi, Agnès Gruart, Polynikis Kaimakis, Cécile Allet, Linda Serra, Paolo Giacobini, José M Delgado‐García, Paola Bovolenta, and Michèle Studer. Mouse nr2f1 haploinsufficiency unveils new pathological mechanisms of a human optic atrophy syndrome. EMBO Molecular Medicine, Jul 2019. URL: https://doi.org/10.15252/emmm.201910291, doi:10.15252/emmm.201910291. This article has 46 citations and is from a highest quality peer-reviewed journal.

7. (chen2020nr2f1heterozygousknockout pages 1-2): Chun-An Chen, Wei Wang, Steen E Pedersen, Ayush Raman, Michelle L Seymour, Fernanda R Ruiz, Anping Xia, Meike E van der Heijden, Li Wang, Jiani Yin, Joanna Lopez, Megan E Rech, Richard A Lewis, Samuel M Wu, Zhandong Liu, Fred A Pereira, Robia G Pautler, Huda Y Zoghbi, and Christian P Schaaf. Nr2f1 heterozygous knockout mice recapitulate neurological phenotypes of bosch-boonstra-schaaf optic atrophy syndrome and show impaired hippocampal synaptic plasticity. Human Molecular Genetics, 29(5):705-715, Oct 2020. URL: https://doi.org/10.1093/hmg/ddz233, doi:10.1093/hmg/ddz233. This article has 22 citations and is from a domain leading peer-reviewed journal.

8. (bertacchi2022pathophysiologicalheterogeneityof pages 18-20): Michele Bertacchi, Chiara Tocco, Christian P. Schaaf, and Michèle Studer. Pathophysiological heterogeneity of the bbsoa neurodevelopmental syndrome. Cells, 11:1260, Apr 2022. URL: https://doi.org/10.3390/cells11081260, doi:10.3390/cells11081260. This article has 33 citations.

9. (bertacchi2022pathophysiologicalheterogeneityof pages 15-17): Michele Bertacchi, Chiara Tocco, Christian P. Schaaf, and Michèle Studer. Pathophysiological heterogeneity of the bbsoa neurodevelopmental syndrome. Cells, 11:1260, Apr 2022. URL: https://doi.org/10.3390/cells11081260, doi:10.3390/cells11081260. This article has 33 citations.

10. (jurkute2021pathogenicnr2f1variants pages 20-21): Neringa Jurkute, Michele Bertacchi, Gavin Arno, Chiara Tocco, Ungsoo Samuel Kim, Adam M Kruszewski, Robert A Avery, Emma C Bedoukian, Jinu Han, Sung Jun Ahn, Nikolas Pontikos, James Acheson, Indran Davagnanam, Richard Bowman, Marios Kaliakatsos, Alice Gardham, Emma Wakeling, Ngozi Oluonye, Maddy Ashwin Reddy, Elaine Clark, Elisabeth Rosser, Patrizia Amati-Bonneau, Majida Charif, Guy Lenaers, Isabelle Meunier, Sabine Defoort, Catherine Vincent-Delorme, Anthony G Robson, Graham E Holder, Luc Jeanjean, Antonio Martinez-Monseny, Mariona Vidal-Santacana, Chloé Dominici, Cedric Gaggioli, Nadia Giordano, Matteo Caleo, Grant T Liu, Genomics England Research Consortium, Andrew R Webster, Michèle Studer, and Patrick Yu-Wai-Man. Pathogenic nr2f1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Communications, Jul 2021. URL: https://doi.org/10.1093/braincomms/fcab162, doi:10.1093/braincomms/fcab162. This article has 29 citations and is from a peer-reviewed journal.

11. (tang2025casereporta pages 7-7): Shuyu Tang, Tingshuai Jiang, Wenqi Su, Binqi Tang, Daoman Xiang, and Jie Zhu. Case report: a de novo nr2f1 mutation and clinical characteristics of bosch–boonstra–schaaf optic atrophy syndrome in a chinese patient. Frontiers in Medicine, Jul 2025. URL: https://doi.org/10.3389/fmed.2025.1542548, doi:10.3389/fmed.2025.1542548. This article has 0 citations.

12. (tang2025casereporta pages 6-7): Shuyu Tang, Tingshuai Jiang, Wenqi Su, Binqi Tang, Daoman Xiang, and Jie Zhu. Case report: a de novo nr2f1 mutation and clinical characteristics of bosch–boonstra–schaaf optic atrophy syndrome in a chinese patient. Frontiers in Medicine, Jul 2025. URL: https://doi.org/10.3389/fmed.2025.1542548, doi:10.3389/fmed.2025.1542548. This article has 0 citations.

13. (chen2020nr2f1heterozygousknockout pages 3-3): Chun-An Chen, Wei Wang, Steen E Pedersen, Ayush Raman, Michelle L Seymour, Fernanda R Ruiz, Anping Xia, Meike E van der Heijden, Li Wang, Jiani Yin, Joanna Lopez, Megan E Rech, Richard A Lewis, Samuel M Wu, Zhandong Liu, Fred A Pereira, Robia G Pautler, Huda Y Zoghbi, and Christian P Schaaf. Nr2f1 heterozygous knockout mice recapitulate neurological phenotypes of bosch-boonstra-schaaf optic atrophy syndrome and show impaired hippocampal synaptic plasticity. Human Molecular Genetics, 29(5):705-715, Oct 2020. URL: https://doi.org/10.1093/hmg/ddz233, doi:10.1093/hmg/ddz233. This article has 22 citations and is from a domain leading peer-reviewed journal.

14. (bertacchi2022pathophysiologicalheterogeneityof pages 5-7): Michele Bertacchi, Chiara Tocco, Christian P. Schaaf, and Michèle Studer. Pathophysiological heterogeneity of the bbsoa neurodevelopmental syndrome. Cells, 11:1260, Apr 2022. URL: https://doi.org/10.3390/cells11081260, doi:10.3390/cells11081260. This article has 33 citations.

15. (jurkute2021pathogenicnr2f1variants media 1490a58e): Neringa Jurkute, Michele Bertacchi, Gavin Arno, Chiara Tocco, Ungsoo Samuel Kim, Adam M Kruszewski, Robert A Avery, Emma C Bedoukian, Jinu Han, Sung Jun Ahn, Nikolas Pontikos, James Acheson, Indran Davagnanam, Richard Bowman, Marios Kaliakatsos, Alice Gardham, Emma Wakeling, Ngozi Oluonye, Maddy Ashwin Reddy, Elaine Clark, Elisabeth Rosser, Patrizia Amati-Bonneau, Majida Charif, Guy Lenaers, Isabelle Meunier, Sabine Defoort, Catherine Vincent-Delorme, Anthony G Robson, Graham E Holder, Luc Jeanjean, Antonio Martinez-Monseny, Mariona Vidal-Santacana, Chloé Dominici, Cedric Gaggioli, Nadia Giordano, Matteo Caleo, Grant T Liu, Genomics England Research Consortium, Andrew R Webster, Michèle Studer, and Patrick Yu-Wai-Man. Pathogenic nr2f1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Communications, Jul 2021. URL: https://doi.org/10.1093/braincomms/fcab162, doi:10.1093/braincomms/fcab162. This article has 29 citations and is from a peer-reviewed journal.

16. (chen2020nr2f1heterozygousknockout pages 11-12): Chun-An Chen, Wei Wang, Steen E Pedersen, Ayush Raman, Michelle L Seymour, Fernanda R Ruiz, Anping Xia, Meike E van der Heijden, Li Wang, Jiani Yin, Joanna Lopez, Megan E Rech, Richard A Lewis, Samuel M Wu, Zhandong Liu, Fred A Pereira, Robia G Pautler, Huda Y Zoghbi, and Christian P Schaaf. Nr2f1 heterozygous knockout mice recapitulate neurological phenotypes of bosch-boonstra-schaaf optic atrophy syndrome and show impaired hippocampal synaptic plasticity. Human Molecular Genetics, 29(5):705-715, Oct 2020. URL: https://doi.org/10.1093/hmg/ddz233, doi:10.1093/hmg/ddz233. This article has 22 citations and is from a domain leading peer-reviewed journal.

17. (kocaaga2022novelnr2f1variant pages 1-1): Ayca Kocaaga, Sevgi Yimenicioglu, and Haluk Hüseyin Gürsoy. Novel nr2f1 variant identified by whole-exome sequencing in a patient with bosch–boonstra–schaaf optic atrophy syndrome. Indian Journal of Ophthalmology, 70:2762-2764, Jun 2022. URL: https://doi.org/10.4103/ijo.ijo_1061_22, doi:10.4103/ijo.ijo_1061_22. This article has 4 citations and is from a peer-reviewed journal.

18. (jurkute2021pathogenicnr2f1variants media 412f5e0a): Neringa Jurkute, Michele Bertacchi, Gavin Arno, Chiara Tocco, Ungsoo Samuel Kim, Adam M Kruszewski, Robert A Avery, Emma C Bedoukian, Jinu Han, Sung Jun Ahn, Nikolas Pontikos, James Acheson, Indran Davagnanam, Richard Bowman, Marios Kaliakatsos, Alice Gardham, Emma Wakeling, Ngozi Oluonye, Maddy Ashwin Reddy, Elaine Clark, Elisabeth Rosser, Patrizia Amati-Bonneau, Majida Charif, Guy Lenaers, Isabelle Meunier, Sabine Defoort, Catherine Vincent-Delorme, Anthony G Robson, Graham E Holder, Luc Jeanjean, Antonio Martinez-Monseny, Mariona Vidal-Santacana, Chloé Dominici, Cedric Gaggioli, Nadia Giordano, Matteo Caleo, Grant T Liu, Genomics England Research Consortium, Andrew R Webster, Michèle Studer, and Patrick Yu-Wai-Man. Pathogenic nr2f1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Communications, Jul 2021. URL: https://doi.org/10.1093/braincomms/fcab162, doi:10.1093/braincomms/fcab162. This article has 29 citations and is from a peer-reviewed journal.

19. (jurkute2021pathogenicnr2f1variants media 964f2122): Neringa Jurkute, Michele Bertacchi, Gavin Arno, Chiara Tocco, Ungsoo Samuel Kim, Adam M Kruszewski, Robert A Avery, Emma C Bedoukian, Jinu Han, Sung Jun Ahn, Nikolas Pontikos, James Acheson, Indran Davagnanam, Richard Bowman, Marios Kaliakatsos, Alice Gardham, Emma Wakeling, Ngozi Oluonye, Maddy Ashwin Reddy, Elaine Clark, Elisabeth Rosser, Patrizia Amati-Bonneau, Majida Charif, Guy Lenaers, Isabelle Meunier, Sabine Defoort, Catherine Vincent-Delorme, Anthony G Robson, Graham E Holder, Luc Jeanjean, Antonio Martinez-Monseny, Mariona Vidal-Santacana, Chloé Dominici, Cedric Gaggioli, Nadia Giordano, Matteo Caleo, Grant T Liu, Genomics England Research Consortium, Andrew R Webster, Michèle Studer, and Patrick Yu-Wai-Man. Pathogenic nr2f1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Communications, Jul 2021. URL: https://doi.org/10.1093/braincomms/fcab162, doi:10.1093/braincomms/fcab162. This article has 29 citations and is from a peer-reviewed journal.

20. (jurkute2021pathogenicnr2f1variants media 3c2b8d85): Neringa Jurkute, Michele Bertacchi, Gavin Arno, Chiara Tocco, Ungsoo Samuel Kim, Adam M Kruszewski, Robert A Avery, Emma C Bedoukian, Jinu Han, Sung Jun Ahn, Nikolas Pontikos, James Acheson, Indran Davagnanam, Richard Bowman, Marios Kaliakatsos, Alice Gardham, Emma Wakeling, Ngozi Oluonye, Maddy Ashwin Reddy, Elaine Clark, Elisabeth Rosser, Patrizia Amati-Bonneau, Majida Charif, Guy Lenaers, Isabelle Meunier, Sabine Defoort, Catherine Vincent-Delorme, Anthony G Robson, Graham E Holder, Luc Jeanjean, Antonio Martinez-Monseny, Mariona Vidal-Santacana, Chloé Dominici, Cedric Gaggioli, Nadia Giordano, Matteo Caleo, Grant T Liu, Genomics England Research Consortium, Andrew R Webster, Michèle Studer, and Patrick Yu-Wai-Man. Pathogenic nr2f1 variants cause a developmental ocular phenotype recapitulated in a mutant mouse model. Brain Communications, Jul 2021. URL: https://doi.org/10.1093/braincomms/fcab162, doi:10.1093/braincomms/fcab162. This article has 29 citations and is from a peer-reviewed journal.

21. (li2024effectivetreatmentof pages 14-15): Xiao Li, Kai Gao, Yutang Li, Yuehua Zhang, Han Zhang, and Yuwu Jiang. Effective treatment of nr2f1-related epilepsy with perampanel. Acta Epileptologica, Jan 2024. URL: https://doi.org/10.1186/s42494-023-00145-0, doi:10.1186/s42494-023-00145-0. This article has 2 citations.

22. (li2024effectivetreatmentof pages 15-17): Xiao Li, Kai Gao, Yutang Li, Yuehua Zhang, Han Zhang, and Yuwu Jiang. Effective treatment of nr2f1-related epilepsy with perampanel. Acta Epileptologica, Jan 2024. URL: https://doi.org/10.1186/s42494-023-00145-0, doi:10.1186/s42494-023-00145-0. This article has 2 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03
• Edison artifact artifact-04
• Edison artifact artifact-05